Use of secondary medical prophylaxis and clinical outcome among patients with ischemic stroke: A nationwide follow-up study

Stroke

Volumn 43, Issue 3, 2012, Pages 802-807

  Palnum, Kaare Haurvig ^a   Mehnert, Frank ^a   Andersen, Grethe ^a   Ingeman, Annette ^b   Krog, Birgitte Randrup ^b   Bartels, Paul Daniel ^b   Johnsen, Søren Paaske ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NIP Secretariat   (Denmark)

Author keywords

effectiveness; ischemic stroke; medical prophylaxis; secondary prevention

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; DRUG USE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; SECONDARY PREVENTION;

AGED; ANTICOAGULANTS; ANTIHYPERTENSIVE AGENTS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; DATA INTERPRETATION, STATISTICAL; DENMARK; FEMALE; FOLLOW-UP STUDIES; GUIDELINES AS TOPIC; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT DISCHARGE; PLATELET AGGREGATION INHIBITORS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84857653879     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.635342     Document Type: Article

References (33)

1. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke. 2008;39:1647-1652.
2. ESO Guidelines for Stroke Management-January 2009. European Stroke Organisation web site. Available at: www.eso-stroke.org/recommendations.php?cid= 9&sid=1. 2009. Accessed February 5, 2010.
3. Ding D, Lu CZ, Fu JH, Hong Z. Association of antiplatelet therapy with lower risk of death and recurrent cerebrovascular events after ischemic stroke-results from the China Ischemic Stroke Registry Study. Circ J. 2009;73:2342-2347.
4. Ding D, Lu CZ, Fu JH, Hong Z. Predictors of vascular events after ischemic stroke: the China ischemic stroke registry study. Neuroepidemiology. 2010;34:110-116.
5. Kong FY, Tao WD, Hao ZL, Liu M. Predictors of one-year disability and death in Chinese hospitalized women after ischemic stroke. Cerebrovasc Dis. 2010;29:255-262.
6. Lingsma HF, Steyerberg EW, Scholte Op Reimer WJ, van DR, Dippel DW. Statin treatment after a recent TIA or stroke: is effectiveness shown in randomized clinical trials also observed in everyday clinical practice? Acta Neurol Scand. 2010;122:15-20.
7. Raine R, Wong W, Ambler G, Hardoon S, Petersen I, Morris R, et al. Sociodemographic variations in the contribution of secondary drug prevention to stroke survival at middle and older ages: cohort study. BMJ. 2009;338:b1279.
8. Toschke AM, Gulliford MC, Wolfe CD, Rudd AG, Heuschmann PU. Antihypertensive treatment after first stroke in primary care: results from the General Practitioner Research Database. J Hypertens. 2011;29:154-160.
9. Lamassa M, Di CA, Pracucci G, Basile AM, Trefoloni G, Vanni P, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke. 2001;32:392-398.
10. Ovbiagele B, Saver JL, Bang H, Chambless LE, Nassief A, Minuk J, et al. Statin treatment and adherence to national cholesterol guidelines after ischemic stroke. Neurology. 2006;66:1164-1170.
11. Lalouschek W, Lang W, Greisenegger S, Mullner M. Determination of lipid profiles and use of statins in patients with ischemic stroke or transient ischemic attack. Stroke. 2003;34:105-110.
12. Simpson CR, Wilson C, Hannaford PC, Williams D. Evidence for age and sex differences in the secondary prevention of stroke in Scottish primary care. Stroke. 2005;36:1771-1775.
13. Pedersen CB, Gotzsche H, Moller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull. 2006;53:441-449.
14. Mainz J, Krog BR, Bjornshave B, Bartels P. Nationwide continuous quality improvement using clinical indicators: the Danish National Indicator Project. Int J Qual Health Care. 2004;16(suppl 1): i45-i50.
15. Lindenstrøm L, Boysen G, Christiansen LW, á Rogvi-Hansen B, Nielsen PW. Reliability of Scandinavian Neurological Stroke Scale. Cerebrovasc Dis. 1991;1:103-107.
16. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999;46:263-268.
17. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
18. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492-499.
19. Royston P. Multiple imputation of missing values: update of ice. Stata J. 2005;5:527-536.
20. White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med. 2009;28:1982-1998.
21. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis. J Am Coll Cardiol. 2008;51:37-45.
22. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. Am J Med. 2008;121:43-49.
23. van WC, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke. 2009;40:1410-1416.
24. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA. 2003;290:2685-2692.
25. Darkow T, Vanderplas AM, Lew KH, Kim J, Hauch O. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin. 2005;21:1583-1594.
26. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37:1070-1074.
27. Lakshminarayan K, Solid CA, Collins AJ, Anderson DC, Herzog CA. Atrial fibrillation and stroke in the general Medicare population: a 10-year perspective (1992 to 2002). Stroke. 2006;37:1969-1974.
28. Parkash R, Wee V, Gardner MJ, Cox JL, Thompson K, Brownell B, et al. The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study. Can J Cardiol. 2007;23:457-461.
29. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation. 2005;112:1687-1691.
30. Klungel OH, Heckbert SR, Longstreth WT Jr, Furberg CD, Kaplan RC, Smith NL, et al. Antihypertensive drug therapies and the risk of ischemic stroke. Arch Intern Med. 2001;161:37-43.
31. Yu AY, Keezer MR, Zhu B, Wolfson C, Cote R. Pre-stroke use of antihypertensives, antiplatelets, or statins and early ischemic stroke outcomes. Cerebrovasc Dis. 2009;27:398-402.
32. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, et al. Effects of beta blockers and calcium-channel blockers on withinindividual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9:469-480.
33. Webb AJ, Rothwell PM. Effect of dose and combination of antihypertensives on interindividual blood pressure variability: a systematic review. Stroke. 2011;42:2860-2865.